Evidence map›Paper›PMID 41496549›Full record

ArticlemAbs2026

Multidimensional maturation of antibody variable domains with machine-learning assistance.

Tomoyuki Ito, Sakiya Kawada, Hikaru Nakazawa, Akikazu Murakami, Mitsuo Umetsu

Abstract read
In one paragraph

Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tomoyuki ItoDepartment of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan.ORCID 0000-0001-8117-5504
Sakiya KawadaDepartment of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan.
Hikaru NakazawaDepartment of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan.ORCID 0000-0003-2785-237X
Akikazu MurakamiDepartment of Oral Microbiology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.ORCID 0000-0003-3064-3237
Mitsuo UmetsuDepartment of Biomolecular Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan.ORCID 0000-0003-4390-0263

Funding

Japan Agency for Medical Research and Development 23AE0121003H0003Japan Society for the Promotion of Science JP20H00315Japan Society for the Promotion of Science JP24K01260New Energy and Industrial Technology Development Organization 20000157-0New Energy and Industrial Technology Development Organization 23201802-0
6 · The paper itself

Abstract

In antibody development, a mutagenesis approach has been widely used to improve affinity, but such mutations often compromise biophysical properties. Here, we combined molecular evolution with machine learning to simultaneously improve affinity and expression level of camelid heavy-chain antibody variable domains (VHHs). Using phage display and deep sequencing, we selected five residues in an anti-SARS-CoV-2 VHH for affinity maturation. We constructed training data using experimentally measured expression levels and target affinities of 117 variants with randomized residues. Machine-learning-predicted top-rank variants showed improved expression level and affinity compared to variants in the training data. Several variants achieved 50-70-fold stronger affinities in the pico-molar range and 4-5-fold higher expression level than wild-type. Furthermore, one variant showed 9.5°C improvement in thermal stability. These results highlight the utility of machine learning-assisted molecular evolution as a strategy for multidimensional optimization of antibody properties.

Indexed as

Antibodies, ViralDirected Molecular EvolutionImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionMachine LearningSARS-CoV-2AnimalsAntibody AffinityHumansPeptide LibraryAntibodies, ViralImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionPeptide LibraryDeep sequencingmachine learningphage displaySARS-CoV-2VHH

Identifiers

PMID41496549
PMCPMC12785217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.